A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Here are two beaten-down stocks that long-term investors might want to consider buying on the dip and holding for several ...

But Pfizer's stock price recently bounced on its second-quarter earnings. Investors have been looking for a glimpse into Pfizer's future, and there is a lot to like as things begi ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Keep in mind, though, that many steep dividend yields are due to the underlying stock having fallen, and Pfizer is a clear ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...